Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants

Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants

The emergence of SARS-CoV-2 variants may impact the effectiveness of vaccines, while heterologous vaccine strategy is considered to provide better protection. The immunogenicity of an mRNA-inactivated virus vaccine against the SARS-CoV-2 wild-type (WT) and variants was evaluated in the study. SARS-C...

Full description

Bibliographic Details
Main Authors: Ruiqi Zhang, Danlei Liu, Ka-Yi Leung, Yujing Fan, Lu Lu, Pui-Chun Chan, Kelvin Kai-Wang To, Honglin Chen, Kwok-Yung Yuen, Kwok-Hung Chan, Ivan Fan-Ngai Hung
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Vaccines
Subjects:
COVID-19
heterologous vaccination
variants
neutralizing antibody
Online Access:https://www.mdpi.com/2076-393X/10/1/72

Internet

https://www.mdpi.com/2076-393X/10/1/72

Similar Items